Liver-specific contrast media: A magic bullet or a weapon for dedicated targets?

Radiology

Volumn 205, Issue 2, 1997, Pages 319-322

  Laniado, Michael ^a   Kopp, Andreas F ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Contrast media; Editorials; Liver, CT, 761.12112; Liver, MR, 761.12143

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM ETHOXYBENZYL DTPA; GADOLINIUM PENTETATE; PENTETIC ACID; YTTERBIUM ETHOXYBENZYL DTPA;

ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; DOG; LIVER; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY;

ANIMALS; CONTRAST MEDIA; DOGS; GADOLINIUM DTPA; LIVER; MAGNETIC RESONANCE IMAGING; PENTETIC ACID; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031278272     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.205.2.9356609     Document Type: Article

References (40)

1. Mitchell DG. Hepatobiliary contrast material: a magic bullet for sensitivity and specificity? Radiology 1993; 188:21-22.
2. Weissleder R. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994; 193:593-595.
3. Lee FT, Chosy SG, Naidu SG, et al. CT depiction of experimental liver tumors: contrast enhancement with hepatocyte-selective iodinated triglyceride versus conventional techniques. Radiology 1997; 203:465-470.
4. Seltzer SE, Blau M, Herman LW, et al. Contrast material-carrying liposomes: biodistribution, clearance, and imaging characteristics. Radiology 1995; 194:775-781.
5. Weichert JP, Longino MA, Spigarelli MG, Lee FT, Schwendner SW, Counsell RE. Computed tomography scanning of Morris hepatomas with liver-specific polyiodinated triglycerides. Acad Radiol 1996; 3:412-417.
6. Schmitz SA, Häberle JH, Balzer T, Shamsi K, Boese Landgraf J, Wolf KJ. Detection of focal liver lesions: CT of the hepatobiliary system with gadoxetic acid disodium, or Gd-EOB-DTPA. Radiology 1997; 202:399-405.
7. Van Beers BE, Gallez B, Pringot J. Contrast-enhanced MR imaging of the liver. Radiology 1997; 203:297-306.
8. Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Bollow M, Wolf KJ. Gd-EOB-DTPA and Yb-EOB-DTPA: two prototypic contrast media for CT detection of liver lesions in dogs. Radiology 1997; 205:361-366.
9. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
10. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199:177-183.
11. Lauffer RB, Greif WL, Stark DD, et al. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies. J Comput Assist Tomogr 1985; 9:431-438.
12. Fisher HW. Improvement in radiographic contrast media through the development of colloidal or particulate media: an analysis. J Theor Biol 1977; 67:653-670.
13. Kuszyk BS, Bluemke DA, Urban BA, et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR 1996; 166:91-95.
14. Van HL, Bosnians H, Aerts P, et al. Focal liver lesions: fast T2-weighted MR imaging with half-Fourier rapid acquisition with re laxation enhancement. Radiology 1996; 201:817-823.
15. Bruneton JN, Falewee MM, Francois E, et al. Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. Radiology 1989; 170:179-183.
16. Miller DL, Vermess M, Doppman JL, et al. CT of the liver and spleen with EOE-13: review of 225 examinations. AJR 1984; 143:235-243.
17. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988; 168:297-301.
18. Kopp AF, Laniado M, Aicher KP, Grönewäller EF, Claussen CD. Mangan-DPDP als kontrastmittel für die MR-tomographie fokaler Leberläsionen. Fortschr Röntgenstr 1992; 157:539-547.
19. Torres CG, Lundby B, Tufte Sterud A, McGill S, Gordon PB, Strand Bjerknes H. MnDPDP for MR imaging of the liver: results of an independent image evaluation of the European phase III studies. Acta Radiol 1997; 38:631-637.
20. Blakeborough A, Ward J, Wilson D, et al. Hepatic lesion detection at MR imaging: a comparative study with four sequences. Radiology 1997; 203:759-765.
21. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 1997; 204:749-756.
22. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzylpropionictetra-acetat (BOPTA) - preliminary results of phase II clinical application. Radiology 1996; 199:513-520.
23. Bernardino ME, Young SW, Lee JK, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:53-58.
24. Oudkerk M, Van den Heuvel AG, Wielopolski PA, Schmitz PIM, Borel Rinkes IHM, Wiggers T. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 1997; 203:449-456.
25. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CTAP. Radiology 1996; 200:785-792.
26. Deckers F, Corthouts E, Nackaerts Y, Ozsarlak O, Parizel PM, De Schepper AM. The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol 1997; 7:1-6.
27. Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196:471-478.
28. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994; 190:417-423.
29. Schima W, Saini S, Echeverri JA, Hahn PF, Harisinghani M, Mueller PR. Focal liver lesions: characterization with conventional spin-echo versus fast spin-echo T2-weighted MR imaging. Radiology 1997; 202:389-393.
30. Denys A, Arrive L, Servois V. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994; 193:665-669.
31. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59-67.
32. Reimer P, Rummeny E, Marx C, et al. Characterization of focal liver lesions with Resovist as a new SPIO: clinical value of dynamic enhancement with T1- and T2-weighted MRI (abstr). Eur Radiol 7:S293.
33. Kettritz U, Schlund JF, Wilbur K, Eisenberg LB, Semelka RC. Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results. Magn Reson Imaging 1996; 14:1185-1190.
34. Soyer P. Will ferumoxides-enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? prologue to a promising future. Radiology 1997; 201:610-611.
35. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-946.
36. Schulz W, Borchard F. Größe der lebermetastasen bei geringer metastasenzahl: eine quantitative Studie an postmortalen lebern. Fortschr Röntgenstr 1992; 156:320-324.
37. Redvanly RD, Jones MT, Chezmar JL. Prevalence and significance of <10 mm liver lesions on spiral CT in patients with clorectal cancer. Presented at the 97th Annual Meeting of the American Roentgen Ray Society, Boston, Mass, May 4-9, 1997.
38. Seifert JK, Junginger T. Resektion von lebermetastasen kolorektaler Tumoren: eine uni- und multivariate analyse von prognosefaktoren. Langenbecks Arch Chir 1996; 381:187-200.
39. Semelka RC, Schlund JF, Molina PL, et al. Malignant liver lesions: comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. JMRI 1996; 6:39-43.
40. Ferrucci JT. Liver tumor imaging: current concepts. AJR 1990; 155:473-484.